Telbivudine: A new treatment for chronic hepatitis B

Table 1 Efficacy at 1 yr in HBeAg positive and HBeAg negative individuals in the Globe study receiving telbivudine or lamivudine

	Telbivudine	Lamivudine	P value
HBeAg positive patients
HBV DNA fall (mean log10)	-6.5	-5.5	< 0.01
HBV DNA non-detectable by PCR (%)	60	40	< 0.01
Treatment failure (%)1	5	13	< 0.01
HBeAg negative patients
HBV DNA fall (mean log10)	-5.2	-4.4	< 0.01
HBV DNA non-detectable by PCR (%)	88	71	< 0.01
Treatment failure (%)1	< 1	3	NS

¹Defined as HBV DNA > 5 log₁₀ copies/mL.

Table 2 Efficacy at 1 yr against virological suppression at 24 wk in HBeAg positive and negative individuals in the Globe study

	Virological suppression at wk 24 (%)
	< 300copies/mL	300-1000copies/mL	> 1000-10 000copies/mL	> 10 000copies/mL
HBeAg positive patients (wk 52)
HBV DNA (< 300 copies/mL)	90	70	30	5
ALT normalization	90	89	80	54
Viral breakthrough	1	3	8	11
HBeAg negative patients (wk 52)
HBV DNA (< 300 copies/mL)	93	66	38	10
ALT normalization	83	74	63	36
Viral breakthrough	0	9	18	32

Table 3 Efficacy at 2 yr in HBeAg positive and HBeAg negative individuals in the Globe study receiving Telbivudine or lamivudine

	Telbivudine	Lamivudine	P value
HBeAg positive patients
HBV DNA fall (mean log10)	-5.7	-4.4	< 0.05
HBV DNA non-detectable by PCR (%)	54	38	< 0.05
Treatment failure (%)1	4	12.3	< 0.05
HBeAg negative patients
HBV DNA fall (mean log10)	-5	-4.2	< 0.05
HBV DNA non-detectable by PCR (%)	79	53	< 0.05
Treatment failure (%)1	0	3	< 0.05

¹Defined as HBV DNA > 5 log10 copies/mL.

Table 4 Efficacy at 2 yr against virological suppression (PCR negative) at 24 wk in HBeAg positive and negative individuals in the Globe study

	Yr 2 outcome	Probability (%)
HBeAg positive	HBeAg seroconversion	45
	ALT normalization	79
	HBV DNA non-detectable by PCR	77
HBeAg negative	ALT normalization	77
	HBV DNA non-detectable by PCR	74